Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles

Informacje na temat projektu

EVCA

Identyfikator umowy o grant: 101079264

DOI

10.3030/101079264

Projekt został zamknięty

Data podpisania przez KE 9 Września 2022

Data rozpoczęcia 1 Listopada 2022

Data zakończenia 30 Kwietnia 2026

Finansowanie w ramach

• Widening participation and spreading excellence

Koszt całkowity

€ 1 487 209,13

Wkład UE

€ 1 487 208,75

Koordynowany przez

UNIVERSIDADE NOVA DE LISBOA
Portugal

Periodic Reporting for period 1 - EVCA (Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles)

Okres sprawozdawczy: 2022-11-01 do 2024-01-31

Podsumowanie kontekstu i ogólnych celów projektu

Advancing Medical Research with Extracellular Vesicles

EVCA, which stands for Extracellular Vesicles in Clinical Applications, is a project focused on using tiny particles called extracellular vesicles (EVs) to improve diagnostics and therapies. The project's full title is "Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles".

The main goal of EVCA is to help NOVA Medical School (NMS) become a world-renowned center for using EVs in medical research and treatments. To achieve this, NMS is collaborating with two top research institutions: Institut Curie in France and CIC bioGUNE in Spain.

Through this partnership, EVCA aims to:

1. Combine the diverse knowledge and experience from each institution.
2. Share the best practices in research and training.
3. Expand collaborative networks.
4. Enhance the skills and management of researchers at NMS.
5. Establish new medical research areas with focus on EVs.

In essence, EVCA is working to push the boundaries of medical science by making NMS a leader in the innovative use of extracellular vesicles for clinical purposes.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

To achieve the above-mentioned objectives, EVCA consortium members have executed a wide range of activities:

1. Seed money for internal projects targeting medical questions by applying EV research was provided through a competitive call.
2. Training of senior and early-career researchers in state-of-the-art EV research methodologies.
3. A summer school was organized, which will soon take place at NMS.
4. Staff exchange programs were executed to improve the management of research.
5. Scientific conferences, outreach activities to the general public, and participation in national and international conferences were supported through competitive calls.
6. Applications for international grants were submitted to enable the consortium to continue activities in the long run. A Marie Curie staff exchange program, were approved.
7. One provisional patent was submitted, and another one is in the planning stage.
8. Three research papers were accepted, and three are currently under review.
9. Two clinical consortia were established to test novel EV-based diagnostic methods for cancer.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

EVCA has developed novel quality control measures, which are essential for moving EV research to the clinic. Furthermore, a novel EV enrichment methodology was established, which we have demonstrated can be interfaced with omics technologies. Finally, we are moving forward in our attempts to provide evidence of clinical usability for novel EV-based early detection methods for cancer.